The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract pharmacy restrictions as part of an ongoing congressional probe of the drug pricing program.
Sen. Cassidy Mum on Next Steps for 340B Provider Probes
The influential senator who launched an inquiry into how two community health centers and two 340B hospitals use 340B savings [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
